Personalized medicine: What’s in it for rare diseases?

Advances in Experimental Medicine and Biology

Volumn 1031, Issue , 2017, Pages 387-404

  Schee Genannt Halfmann, Sebastian ^a   Mählmann, Laura ^a,b   Leyens, Lada ^a,c   Reumann, Matthias ^a,d   Brand, Angela ^a,e  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF BASEL   (Switzerland)

^c Swissmedic   (Switzerland)

^d IBM RESEARCH ZURICH   (Switzerland)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Actionable big data analytics; Health data cooperatives; Managed entry agreement; Personalized medicine; Rare disease; Systematic early dialogue

Indexed keywords

CARDIOLOGY; CLINICAL RESEARCH; EMPOWERMENT; EUROPEAN UNION; HEALTH CARE MANAGEMENT; HEALTH CARE SYSTEM; HUMAN; NUTRITION; ONCOLOGY; PATIENT CARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RARE DISEASE; DATA MINING; FACTUAL DATABASE; GENETIC PREDISPOSITION; GENETICS; GENOMICS; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; REGISTER; RISK FACTOR; TRANSLATIONAL RESEARCH;

DATA MINING; DATABASES, FACTUAL; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; PHENOTYPE; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RARE DISEASES; REGISTRIES; RISK FACTORS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85037663316     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-67144-4_22     Document Type: Chapter

References (60)

1. Alyass A, Turcotte M, Meyre D (2015) From big data analysis to personalized medicine for all: challenges and opportunities. BMC Med Genet 8(1): 33
2. Auffray C, Balling R, Barroso I, Bencze L, Benson M, Bergeron J, Bernal-Delgado E, Blomberg N, Bock C, Conesa A (2016) Making sense of big data in health research: towards an EU action plan. Genome Med 8(1): 1
3. Bereczki D (2012) Personalized medicine: a competitor or an upgrade of evidence-based medicine? Per Med 9(2): 211-221
4. Boycott KM, Vanstone MR, Bulman DE, MacKenzie AE (2013) Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet 14(10): 681-691
5. Cutica I, Mc Vie G, Pravettoni G (2014) Personalised medicine: the cognitive side of patients. Eur J Intern Med 25(8): 685-688
6. Directorate-General for Internal Policies - European Parliament (2015) Towards a harmonised EU assessment of the added therapeutic value of medicines. European Parliament, Brussels
7. Estape EA, Mays MH, Sternke EA (2016) Translation in data mining to advance personalized medicine for health equity. Intell Inf Manag 8(01): 9
8. European Alliance for Personalised Medicine (2013) Innovation and patient access to personalised medicine. Report from Irish Presidency Conference Brussels
9. European Alliance for Personalised Medicine (2014) MEP’s Briefing Paper 2014-2019 Legislature
10. European Commission (2016) European networks of reference for rare diseases. http:// ec.europa.eu/health/rare_diseases/european_reference_networks/erf_en. Accessed 7 Dec 2016
11. European Commission (2014) The use of big data in public health policy research
12. European Commission (2016) Towards an International Consortium for Personalised Medicine (IC PerMed)
13. European Commission (2012) Biobanks for Europe. A challenge for governance Belgium
14. European Commission (2013) Use of "-omics” technologies in the development of personalised medicine Belgium
15. European Commission (2014) Advice for 2016/2017 of the Horizon 2020 advisory group for societal challenge 1, “Health, Demographic Change and Wellbeing”
16. European Federation of Pharmaceutical Industries and Associations (2014) What are Medicines Adaptive Pathways to Patients (MAPPs)?
17. European Federation of Pharmaceutical Industries and Associations (2010) Patients W.A.I.T. Indicator
18. European Science Foundation (2012) Personalised medicine for the European citizen. Towards more precise medicine for the diagnosis, treatment and prevention of disease (iPM) European Science Foundation, Strasbourg November
19. Ferrario A, Kanavos P (2013) Managed entry agreements for pharmaceuticals: the European experience. London school of economics and political science 154
20. Francioso S, Almerighi C, Forte P, Bandiera F, Nosotti L, Lionetti R, Taliani G, Piras MR, Ponti ML, Parruti G (2014) A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: the TT4 randomized trial. Dig Liver Dis 46(2): 164-169
21. Gantz J, Reinsel D (2012) The digital universe in 2020: big data, bigger digital shadows, and biggest growth in the far east. IDC iView: IDC Analyze the future 2007: 1-16
22. Garfield S (2011) Advancing access to personalized medicine: a comparative assessment of European reimbursement systems. Personalized Medicine Coalition Bridgehead International
23. Gomes L (2015) Tech giants bet on biometrics. IEEE Spectr 52(6): 52-55
24. Hafen E, Kossmann D, Brand A (2014) Health data cooperatives-citizen empowerment. Methods Inf Med 53(8)
25. Horgan D, Jansen M, Leyens L, Lal JA, Sudbrak R, Hackenitz E, Bußhoff U, Ballensiefen W, Brand A (2014) An index of barriers for the implementation of personalised medicine and pharmacogenomics in Europe. Public Health Genomics 17(5-6): 287-298
26. Horgan D, Paradiso A, McVie G, Banks I, Van der Wal T, Brand A, Lawler M (2015) Is precision medicine the route to a healthy world? Lancet 386(9991): 336-337
27. Ianuale C, Leoncini E, Mazzucco W, Marzuillo C, Villari P, Ricciardi W, Boccia S (2014) Public health genomics education in post-graduate schools of hygiene and preventive medicine: a cross-sectional survey. BMC Med Educ 14(1): 213
28. IDC (2016) Big data and analytics is increasingly a game of inches. https://www.idc.com/ prodserv/4Pillars/bigdata
29. Intel (2013) Care customization: Appying big data to clinical analytics and life sciences
30. Kanavos P, Vandoros S, Irwin R, Nicod E, Casson M (2011) Differences in costs of and access to pharmaceutical products in the EU
31. Kickbusch I, Wait S, Maag D, Banks I (2006) Navigating health. The role of health literacy. Alliance for Health and the Future, International Longevity Centre-UK, London
32. Lehrach H (2015) Virtual clinical trials, an essential step in increasing the effectiveness of the drug development process. Public Health Genomics 18(6): 366-371
33. Lehrach H (2012) A revolution in healthcare: challenges and opportunities for personalized medicine. Per Med 9(2): 105-108
34. Leopold C, Vogler S, Habl C, Mantel-Teeuwisse A, Espin J (2013) Personalised medicine as a challenge for public pricing and reimbursement authorities-a survey among 27 European countries on the example of trastuzumab. Health Policy 113(3): 313-322
35. Leyens L, Brand A (2016) Early patient access to medicines: health technology assessment bodies need to catch up with new marketing authorization methods. Public Health Genomics 19(3): 187-191
36. Leyens L, Horgan D, Lal JA, Steinhausen K, Satyamoorthy K, Brand A (2014) Working towards personalization in medicine: main obstacles to reaching this vision from today’s perspective. Per Med 11(7): 641-649
37. Leyens L, Reumann M, Malats N, Brand A (2017) Use of big data for drug development and for public and personal health and care. Genet Epidemiol 41(1): 51-60
38. Loscalzo J, Kohane I, Barabasi AL (2007) Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol Syst Biol 3(1): 124
39. Martin-Sanchez F, Verspoor K (2014) Big data in medicine is driving big changes. Yearb Med Inform 9(1): 14-20
40. McGovern L, Miller G, Hughes-Cromwick P (2014) The relative contribution of multiple determinants to health outcomes. Health Aff (Millwood) (2): 1-9. http://healthaffairs.org/ healthpolicybriefs/brief_pdfs/healthpolicybrief_123.pdf
41. McGregor C, James A, Eklund M, Sow DM, Ebling M, Blount M (2013) Real-time multidimensional temporal analysis of complex high volume physiological data streams in the neonatal intensive care unit. In: MedInfo, pp 362-366
42. Meyer M (2015) Digitale chancen: next generation healthcare - siemens keynote
43. Negrouk A, Horgan D, Gorini A, Cutica I, Leyens L, Schee genannt Halfmann S, Pravettoni G (2015) Clinical trials, data protection and patient empowerment in the era of the new EU regulations. Public Health Genomics 18(6): 386-395
44. Ogino S, Fuchs CS, Giovannucci E (2012) How many molecular subtypes? implications of the unique tumor principle in personalized medicine. Expert Rev Med Diagn 12(6): 621-628
45. Palau F (2012) Personalized medicine in rare diseases. Per Med 9(2): 137-141
46. Pavelić K, Martinović T, Pavelić SK (2015) Do we understand the personalized medicine paradigm? EMBO Rep 16(2): 133-136
47. PerMed (2015) Shaping Europe’s vision for personalised medicine - Strategic Research Innovation Agenda (SRIA)
48. Powers Dirette D (2015) Personalized medicine: definitions, history, and implications for the OT profession. Open JOccup Ther 3(4): 1
49. Roden DM (2015) Cardiovascular pharmacogenomics: current status and future directions. J Hum Genet 61(1): 79-85
50. Rometty V (2014) The year of the smarter enterprise. The economist, The world in
51. Rose J, Rehse O, Röber B (2012) The value of our digital identity. Boston Cons Gr
52. Sackett DL, Rosenberg WM, Gray JM, Haynes RB, Richardson WS (1996) Evidence based medicine: what it is and what it isn’t. BMJ 312(7023): 71-72
53. Schleidgen S, Klingler C, Bertram T, Rogowski WH, Marckmann G (2013) What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med Ethics 14(1): 55
54. Schork NJ (2015) Personalized medicine: time for one-person trials. Nature 520(7549): 609-611
55. Snyderman R (2014) Personalized medicine 2014: has healthcare been transformed? Per Med 11(4): 365-368
56. Sørensen K, Pelikan JM, Röthlin F, Ganahl K, Slonska Z, Doyle G, Fullam J, Kondilis B, Agrafiotis D, Uiters E (2015) Health literacy in Europe: comparative results of the European health literacy survey (HLS-EU). Eur J Public Health 25(6): 1053-1058
57. Spear BB, Heath-Chiozzi M, Huff J (2001) Clinical application of pharmacogenetics. Trends Mol Med 7(5): 201-204
58. Taylor D, Al-Saeed E (2010) Can (and will) governments afford personalized medicine? Per Med 7(5): 587-595
59. Turner RM, Pirmohamed M (2014) Cardiovascular pharmacogenomics: expectations and practical benefits. Clin Pharmacol Ther 95(3): 281-293
60. Zhang J, Chiodini R, Badr A, Zhang G (2011) The impact of next-generation sequencing on genomics. J Genet Genomics 38(3): 95-109